Utjecaj inkretinomimetika na kardiovaskularni sustav

master's thesis

• Title (english): Effects of incretin mimetics on the cardiovascular system
• Author: David Novković
• Mentor: Lidija Bach-Rojecky (mentor)
• Committee member: Lidija Bach-Rojecky (predsjednik povjerenstva)
• Committee member: Monika Barbarić (član povjerenstva)
• Committee member: Maja Friščić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmacology); Zagreb
• Defense date and country: 2024-07-16, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Inkretinomimetici, razvijeni po uzoru na endogene inkretine - glukagonu sličan peptid-1 (GLP-1) i o glukozi-ovisan inzulinotropni peptid (GIP), su lijekovi peptidne strukture koji se primarno koriste u liječenju dijabetesa tipa 2 i pretilosti. Oba stanja predstavljaju veliki i rastući javnozdravstveni problem, te su povezana s povećanim rizikom od kardiovaskularnih smrti. Svi lijekovi djeluju kao potentni agonisti receptora za GLP-1, dok je jedino tirzepatid dualni agonist GLP-1 i GIP receptora. Trenutno su za pretilost indicirani samo liraglutid i semaglutid. Lijekovi značajno smanjuju glukozu u krvi i tjelesnu težinu, no zbog široko rasprostranjenih receptora, pokazuje direktne i indirektne pozitivne učinke na različite organske sustave, uključujući i kardiovaskularni sustav. Relevantnost djelovanja inkretinomimetika na pojedini sustav predmet je mnogih istraživanja te, između ostalog, ovisi o farmakodinamici i farmakokinetici lijekova. Do sada su provedene brojne velike randomizirane placebom kontrolirane kliničke studije, kao i meta-analize koje su istraživale djelotvornost i podnošljivost inkretinomimetika u bolesnika s kardiovaskularnim rizicima. Mnoga od njih pokazala su koristi ovih lijekova za određenu populaciju bolesnika, te su podloga za potencijalno širenje indikacija u kliničkoj praksi.

Abstract (english)

Incretin mimetics, developed based on endogenous incretins - glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), are peptide-based drugs primarily used in the treatment of type 2 diabetes and obesity. Both conditions represent major and growing public health concerns and are associated with an increased risk of cardiovascular mortality. All these drugs act as potent GLP-1 receptor agonists, with tirzepatide being the only dual agonist of GLP-1 and GIP receptors. Currently, liraglutide and semaglutide are indicated for obesity. These drugs significantly reduce blood glucose and body weight. Additionally, due to their widespread receptor distribution, they show direct and indirect positive effects on various organ systems, including the cardiovascular system. The relevance of actions on each system is the subject of extensive research, influenced among other factors by the pharmacodynamics and pharmacokinetics of the drugs. To date, numerous large randomized placebo-controlled clinical trials and meta-analyses have been conducted to investigate the efficacy and tolerability of incretin mimetics in patients at cardiovascular risk. Many of these studies have demonstrated the benefits of these drugs for specific patient populations, and are the basis for the potential expansion of indications in clinical practice.

• Keywords: inkretinomimetici; agonisti GLP-1; kardiovaskularni sustav; dijabetes melitus tip 2
• Keywords (english): incretin mimetics; GLP-1 agonists; cardiovascular system; type 2 diabetes mellitus
• Language: croatian
• URN:NBN: urn:nbn:hr:163:514128
• Study programme: Title: Pharmacy - integrated undergraduate and graduate - university study; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: sveučilišni magistar farmacije (sveučilišni magistar farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2024-09-26 13:14:57